Dr Anthony Lui Secures Around HK$1M from Health and Medical Research Fund for Cancer Research
Dr Anthony Lui, Lecturer of the Division of Science, Engineering and Health Studies, secured funding of around HK$1M from the Health and Medical Research Fund (HMRF) under the Food and Health Bureau to launch a two-year research project entitled “Mechanistic Characterisation of the MT2-induced Pgp Inhibition and the Chemosensitization on Combining MT2 with Taxol in Treating Multi-drug Resistant Cancer in Vitro and in Vivo” from October 2021. This is the first time that a CPCE scholar successfully obtained funding from the HMRF.
The project team, led by Dr Lui, has discovered a potent anti-cancer drug called MT2 from Marsdenia Tenacissima, a medicinal plant in Traditional Chinese Medicine (TCM). In this project, the anti-cancer drug mechanism of MT2 to inhibit multi-drug resistant Pgp protein would be elucidated by in vitro assays. Further, its anti-cancer effects would be demonstrated by various multi-drug resistant and non-resistant cancer cell models as well as in animal model. More importantly, synergistic anti-cancer effects would be demonstrated when MT2 could be co-treated with other chemotherapeutic agents, such as Taxol. Its findings would prove that MT2 could be a novel and potent anti-cancer drug that is effective and safe for treating cancer patients in the future.
Dr Anthony Lui says that MT2 is a novel and potent anti-cancer drug which could be effective and safe for treating cancer patients in the future.